A recent article published in the New England Journal of Medicine (NEJM) demonstrated higher response, longer progression free survival and overall survival in patients with unresectable or metastatic leiomyosarcoma. A treatment protocol that we’ve been doing for at least 1-2 years prior given the known higher response rate reported at conferences. This is a new …
Clinical Trials
Dive into the heart of innovation with our “Clinical Trials” subcategory, where we unveil the dynamic world of oncology research in real-time. Discover the latest developments and breakthroughs in cancer treatment as we explore ongoing clinical trials and their potential impact on patient care. Gain insights into the rigorous process of testing novel therapies, uncover promising treatment options, and learn how these trials contribute to advancing the field of oncology. Stay informed and be part of the journey towards more effective and compassionate cancer care.
A Difficult Choice: Hope vs. Quality of Life James is a 62-year-old patient with advanced pancreatic cancer. After enduring multiple rounds of chemotherapy, he finds himself at a crossroads. His oncologist presents him with an option: a new experimental treatment offered through a clinical trial. This treatment carries the potential to extend his life by …
EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) EGFR (epidermal growth factor receptor) is a protein located on the surface of cells that regulates their growth and division. Mutations in the EGFR gene can lead to uncontrolled cell growth and are commonly found in various cancers, including non-small cell lung cancer (NSCLC). In patients with unresectable stage …
Maintaining good health is vital for everyone, but it’s especially crucial for patients diagnosed with cancer. This becomes even more important to those participating in clinical trials, where the physical and mental demands can be significant. Ensuring balanced diet and regular exercise can play a key role in supporting your overall well-being throughout this challenging …
When it comes to battling a rare and aggressive cancer like synovial sarcoma, the treatment options have often been limited—until now. The FDA’s recent approval of Tecelra (Amafi-Cel), the first gene therapy for adults with metastatic synovial sarcoma, not only provides new hope for patients who’ve exhausted other options but also paves the way for …
Deciding to join a clinical trial can feel daunting, especially with the myths and misconceptions that surround them. Let’s take a moment to clear the air and set the record straight about what clinical trials really mean for you as a patient. Myth #1: “I’m Just a Lab Rat” Contrary to popular belief, participating in …
The American Society of Clinical Oncology (ASCO) 2024 conference was a remarkable event, bringing together leading minds in oncology to discuss the latest breakthroughs and research in cancer treatment. This year’s conference was particularly notable for the innovative approaches presented in the treatment of metastatic melanoma, a challenging and aggressive form of skin cancer. In …
New article published in NEJM demonstrated activity of Pembrolizumab adjuvantly given for resected intermediate, poor risk and resected metastatic RCC. Kidney cancer remains a significant health challenge worldwide, with renal-cell carcinoma (RCC) being the most common type. Traditionally, surgery has been the primary treatment for localized kidney cancer, but the risk of recurrence remains high. …
On February 16th 2024, after a roughly 2-3 year wait fully aware of the data and the patient beneficial long term outcomes in a subset of patients, the FDA finally announced the approval of the first cellular therapy approved for solid tumors and specifically TIL in treatment refractory malignant melanoma. TIL using Amtagvi (Lifileucel) is …
New data published in NEJM may new treatment options for patients dealing with metastatic small cell carcinoma! Small-cell lung cancer (SCLC) stands as one of the most aggressive forms of cancer, often leaving patients and their families grappling with limited treatment options and a prognosis that can seem disheartening. But amidst these challenges, there emerges …